 |
Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement
Nov 28, 2001
|
9.8 KB |
| |
INGELHEIM, Germany and CAMBRIDGE, Mass., Nov 28, 2001 /PRNewswire via COMTEX/
Boehringer Ingelheim International GmbH and ImmunoGen, Inc. (Nasdaq: IMGN)
today announced a collaboration to develop a new product combining ImmunoGen's
maytansinoid Tumor-Activated Prodrug (TAP) technology with a Boehringer
Ingelheim antibody. Under the terms of ...
|
|
ImmunoGen, Inc. Reports First-Quarter Results
Nov 8, 2001
|
12.0 KB |
| |
CAMBRIDGE, Mass., Nov. 8 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced financial results for the first quarter ended September 30,
2001. For the three-month period, the Company reported a net loss of
$1,593,000, or $0.04 per share, compared to a net loss before the cumulative
effect of a change in accounting principle of $1,979...
|
|
ImmunoGen Announces Favorable Preliminary Phase I/II Data on huC242-DM1/SB-408075
Nov 1, 2001
|
10.4 KB |
| |
MIAMI BEACH, Fla., Nov. 1, 2001 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced very favorable safety data from the initial 27 patients
enrolled in a human clinical trial of its Tumor-Activated Prodrug (TAP),
huC242-DM1/SB-408075 for the treatment of colorectal, pancreatic, and certain
non-small-cell lung cancers. In addition, ev...
|
|
ImmunoGen's Partner Genentech Presents Favorable Preclinical Results of Trastuzumab-DM1 at AACR-NCI-EORTC Meeting
Nov 1, 2001
|
10.3 KB |
| |
MIAMI BEACH, Fla., Nov. 1, 2001 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced that Trastuzumab-DM1 (Herceptin® conjugated to DM1), a
Tumor-Activated Prodrug (TAP), caused complete tumor regression in HER2
positive xenograft models in mice. In addition, Trastuzumab-DM1 demonstrated
superior...
|
|
ImmunoGen Introduces New Taxane-Based Tumor-Activated Prodrug Platform
Oct 30, 2001
|
10.1 KB |
| |
MIAMI BEACH, Fla., Oct 30, 2001 /PRNewswire via COMTEX/ ---- Data from New Class of Effector Molecules Presented at AACR-NCI-EORTC Meeting -- ImmunoGen, Inc.
(Nasdaq: IMGN) today reported that data from its taxane-based Tumor-Activated
Prodrug (TAP) platform showed exceptional anti-tumor activity in mice. Results
were presen...
|
|
ImmunoGen, Inc. Reports Financial Results for Fiscal Year 2001
Aug 16, 2001
|
14.3 KB |
| |
CAMBRIDGE, Mass., Aug. 16 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced financial results for the three and twelve months ended June
30, 2001. The following fi...
|
|
ImmunoGen & BioInvent Sign Antibody Manufacturing Agreement
Jun 28, 2001
|
12.0 KB |
| |
CAMBRIDGE, Mass. and LUND, Sweden, June 28 /PRNewswire/ -- BioInvent
International AB (SAX: BINV) and ImmunoGen, Inc. (Nasdaq: IMGN) announced
today that they have signed a man...
|
|
MorphoSys and ImmunoGen Expand Existing Collaboration License of HuCAL(R) For Target Research
Jun 21, 2001
|
12.6 KB |
| |
MARTINSRIED/MUNICH, Germany and CAMBRIDGE, Mass., June 21 /PRNewswire/ --
MorphoSys (Neuer Markt: MOR) and ImmunoGen, Inc. (Nasdaq: IMGN) today
announced a research agreement u...
|
|
British Biotech and ImmunoGen Begin Patient Enrollment for the Phase I/II Trial of BB-10901/huN901-DM1 in Small Cell Lung Cancer
May 29, 2001
|
12.5 KB |
| |
CAMBRIDGE, Mass., May 29 /PRNewswire/ -- British Biotech
(LSE: BBG; Nasdaq: BBIOY) and ImmunoGen Inc. (Nasdaq: IMGN) today began
patient enrollment for the Phase I/II clinical ...
|
|
ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers
May 14, 2001
|
10.2 KB |
| |
CAMBRIDGE, Mass., May 14, 2001 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced safety and pharmacokinetic data from 37 patients enrolled in
the first human clini...
|
|
ImmunoGen, Inc. Reports Third Quarter Results, Beating Expectations by $0.01
May 10, 2001
|
13.1 KB |
| |
CAMBRIDGE, Mass., May 10 /PRNewswire/ --ImmunoGen, Inc. (Nasdaq: IMGN)
today announced financial results for the third quarter ended March 31, 2001.
For the three-month period,...
|
|
ImmunoGen Begins Enrollment in a Third Phase I/II Human Clinical Study with Lead Product for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers
May 8, 2001
|
9.8 KB |
| |
CAMBRIDGE, Mass., May 8 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced that it has begun enrollment for a third Phase I/II human
clinical study with huC242-DM1/...
|
|
ImmunoGen and Raven Biotechnologies Announce Target and Antibody Discovery Collaboration in Ovarian Cancer
Mar 29, 2001
|
10.5 KB |
| |
SAN CARLOS, Calif., and CAMBRIDGE, Mass., March 29 /PRNewswire/ --
Raven Biotechnologies, Inc. (Raven) and ImmunoGen, Inc. (Nasdaq: IMGN)
announced today the formation of a col...
|
|
ImmunoGen Appoints New Chief Financial Officer
Mar 5, 2001
|
7.8 KB |
| |
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced the appointment of Gregg D. Beloff as Vice President and Chief
Financial Officer. Mr. ...
|
|
Millennium and ImmunoGen Form Multi-Product Antibody Collaboration
Mar 5, 2001
|
13.5 KB |
| |
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
(Nasdaq: MLNM) and ImmunoGen, Inc. (Nasdaq: ...
|
|
ImmunoGen, Inc. Reports Second Quarter Results
Feb 8, 2001
|
11.3 KB |
| |
CAMBRIDGE, Mass., Feb. 8 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced financial results for the second quarter ended December 31,
2000. For the three-month p...
|
|
ImmunoGen Comments on Recent SEC Lawsuit
Feb 1, 2001
|
8.2 KB |
| |
CAMBRIDGE, Mass., Feb. 1 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
announced today that it has learned from public sources that the Securities
and Exchange Commission has ...
|
|
ImmunoGen and Avalon Enter Genomics-Based Collaboration
Jan 25, 2001
|
8.6 KB |
| |
CAMBRIDGE, Mass., and GAITHERSBURG, Md., Jan. 25 /PRNewswire/ --
ImmunoGen, Inc. (Nasdaq: IMGN) and Avalon Pharmaceuticals, Inc. today
announced that they have entered into a l...
|
| Showing 1-18 of 18 |
Page: 1 |
|
|
